Notice of Lodging of Proposed Consent Decree under the Clean Air Act, 41953 [2013-16752]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 134 / Friday, July 12, 2013 / Notices
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on October 16, 2012, based on a
complaint filed on September 10, 2012,
on behalf of South Alabama Medical
Science Foundation of Mobile, Alabama
(‘‘SASF’’); Merck & Cie of Altdorf,
Switzerland (‘‘Merck’’); and Pamlab LLC
of Covington, Louisiana (‘‘Pamlab’’). 77
FR 63336 (October 16, 2012). The
complaint alleged violations of Section
337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, by reason of
infringement of one or more of claims
37, 39, 40, 47, 66, 67, 73, 76, 78–81, 83,
84, 86–89, 91, 92, 94–97, 99, 100, 110,
111, 113, 117, and 121 of U.S. Patent
No. 5,997,915; claims 22, 26, and 32–38
of U.S. Patent No. 6,673,381; claims 1,
4–6, and 15 of U.S. Patent No.
7,172,778; and claims 1–3, 5, 6, 8, 9, 11–
15, and 19–22 of U.S. Patent No.
6,011,040. The Commission’s notice of
investigation named as respondents
Gnosis SpA of Desio, Italy; Gnosis
Bioresearch SA of Sant’Antonino,
Switzerland; Gnosis USA Inc. of
Doylestown, Pennsylvania; and
Macoven Pharmaceuticals LLC of
Magnolia, Texas.
On December 13, 2012, the
Commission issued notice of its
determination not to review an ID
adding Viva Pharmaceuticals LLC as a
new respondent. On February 4, 2013,
the Commission issued notice of its
determination not to review an ID to
identify the new respondent as Viva
Pharmaceuticals Inc. rather than Viva
Pharmaceuticals LLC.
On May 10, 2013, complainants
SASF, Merck, and Pamlab filed an
unopposed corrected motion for leave to
add Nestle Health Science-Pamlab Inc.
(‘‘NHS-Pamlab’’) as a complainant and
change Pamlab’s name to Camline LLC.
On June 11, 2013, the administrative
law judge issued an ID (Order No. 12)
granting the motion. The administrative
law judge found good cause shown
because NHS-Pamlab has acquired
Pamlab and Pamlab was renamed
following the acquisition. There were no
petitions for review.
Having considered the ID and the
relevant portions of the record, the
Commission has determined not to
review the subject ID. The complaint
and notice of investigation are therefore
VerDate Mar<15>2010
18:46 Jul 11, 2013
Jkt 229001
amended to add a new complainant
NHS-Pamlab and to rename Pamlab as
Camline LLC.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of section 210.42(h) of the
Commission’s Rules of Practice and
Procedure (19 CFR 210.42(h)).
By order of the Commission.
Issued: July 8, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–16707 Filed 7–11–13; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree under the Clean Air
Act
On June 28, 2013, the Department of
Justice lodged a proposed consent
decree with the United States District
Court for the Eastern District of
Tennessee in the lawsuit entitled United
States and State of Tennessee v. King
Pharmaceuticals LLC, Civil Action No.
2:13-cv-00178.
The United States filed this lawsuit
under the Clean Air Act. The complaint
seeks injunctive relief and civil
penalties for alleged violations at the
defendant’s pharmaceutical production
facility in Bristol, Tennessee, of (1)
Permits issued under the Tennessee
State Implementation Plan, (2) federal
emission standards for hazardous air
pollutants for pharmaceutical
production, and (3) Title V of the Clean
Air Act. The consent decree requires the
defendant to perform injunctive relief to
correct the violations at the facility and
to pay $2.2 million in civil penalties, of
which half will go to the United States
and the other half to the State of
Tennessee.
The publication of this notice opens
a period for public comment on the
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States et al. v. King
Pharmaceuticals LLC, D.J. Ref. No. 90–
5–2–1–10132. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By e-mail ......
pubcommentees.enrd@usdoj.gov.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
41953
To submit
comments:
Send them to:
By mail .........
Assistant Attorney General
U.S. DOJ—ENRD
P.O. Box 7611
Washington, D.C. 20044–
7611.
During the public comment period,
the consent decree may be examined
and downloaded at this Justice
Department Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. We will provide
a paper copy of the consent decree upon
written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $13.00 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2013–16752 Filed 7–11–13; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Labor
Organization and Auxiliary Reports
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Office of Labor
Management Standards (OLMS)
sponsored information collection
request (ICR) revision titled, ‘‘Labor
Organization and Auxiliary Reports,’’ to
the Office of Management and Budget
(OMB) for review and approval for use
in accordance with the Paperwork
Reduction Act (PRA) of 1995 (44 U.S.C.
3501 et seq.).
DATES: Submit comments on or before
August 12, 2013.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://www.reg
info.gov/public/do/PRAViewICR?ref_
nbr=201306-1245-001 (this link will
only become active on the day following
publication of this notice) or by
contacting Michel Smyth by telephone
SUMMARY:
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 78, Number 134 (Friday, July 12, 2013)]
[Notices]
[Page 41953]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16752]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed Consent Decree under the Clean Air
Act
On June 28, 2013, the Department of Justice lodged a proposed
consent decree with the United States District Court for the Eastern
District of Tennessee in the lawsuit entitled United States and State
of Tennessee v. King Pharmaceuticals LLC, Civil Action No. 2:13-cv-
00178.
The United States filed this lawsuit under the Clean Air Act. The
complaint seeks injunctive relief and civil penalties for alleged
violations at the defendant's pharmaceutical production facility in
Bristol, Tennessee, of (1) Permits issued under the Tennessee State
Implementation Plan, (2) federal emission standards for hazardous air
pollutants for pharmaceutical production, and (3) Title V of the Clean
Air Act. The consent decree requires the defendant to perform
injunctive relief to correct the violations at the facility and to pay
$2.2 million in civil penalties, of which half will go to the United
States and the other half to the State of Tennessee.
The publication of this notice opens a period for public comment on
the consent decree. Comments should be addressed to the Assistant
Attorney General, Environment and Natural Resources Division, and
should refer to United States et al. v. King Pharmaceuticals LLC, D.J.
Ref. No. 90-5-2-1-10132. All comments must be submitted no later than
thirty (30) days after the publication date of this notice. Comments
may be submitted either by email or by mail:
------------------------------------------------------------------------
To submit comments: Send them to:
------------------------------------------------------------------------
By e-mail........................... pubcomment-ees.enrd@usdoj.gov.
By mail............................. Assistant Attorney General
U.S. DOJ--ENRD
P.O. Box 7611
Washington, D.C. 20044-7611.
------------------------------------------------------------------------
During the public comment period, the consent decree may be
examined and downloaded at this Justice Department Web site: https://www.usdoj.gov/enrd/Consent_Decrees.html. We will provide a paper copy
of the consent decree upon written request and payment of reproduction
costs. Please mail your request and payment to: Consent Decree Library,
U.S. DOJ--ENRD, P.O. Box 7611, Washington, DC 20044-7611.
Please enclose a check or money order for $13.00 (25 cents per page
reproduction cost) payable to the United States Treasury.
Maureen Katz,
Assistant Section Chief, Environmental Enforcement Section, Environment
and Natural Resources Division.
[FR Doc. 2013-16752 Filed 7-11-13; 8:45 am]
BILLING CODE 4410-15-P
